Ceryvyn TherapeuticsASX:CYV -7.69% 9-Day RSI is 7.34 as of Jul. 11, 2026. The stock has 3 warning signs investors should review. Among 1,421 Biotechnology companies, Ceryvyn Therapeutics ranks better than 99.58% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Ceryvyn Therapeutics 9-Day RSI Related Terms
ASX:CYV vs VRTX, REGN, ALNY: 9-Day RSI Comparison
For the Biotechnology subindustry, Ceryvyn Therapeutics's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ceryvyn Therapeutics 9-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ceryvyn Therapeutics's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Ceryvyn Therapeutics's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ceryvyn Therapeutics (ASX:CYV) has a 9-Day RSI of 7.34 as of Jul. 11, 2026. According to the industry distribution chart, Ceryvyn Therapeutics ranks #6 out of 1421 companies in the Biotechnology industry, placing it in the top 0.40000000000001%.
Is Ceryvyn Therapeutics' 9-Day RSI too high?
Ceryvyn Therapeutics' current 9-Day RSI is 7.34. The Biotechnology industry median 9-Day RSI is 49.68. Ceryvyn Therapeutics' value of 7.34 is 85.2% below this industry median. Based on the distribution chart, Ceryvyn Therapeutics ranks #6 out of 1421 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Ceryvyn Therapeutics' 9-Day RSI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ceryvyn Therapeutics ranks #6 out of 1421 companies for 9-Day RSI. This places Ceryvyn Therapeutics in the top 0% of its industry — outperforming the majority of peers. The industry median 9-Day RSI is 49.68. Ceryvyn Therapeutics' value of 7.34 is 85.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Biotechnology company?
The median 9-Day RSI among Biotechnology companies is 49.68, based on 1,421 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ceryvyn Therapeutics's current 9-Day RSI of 7.34 is 85.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 9-Day RSI is 49.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ceryvyn Therapeutics's current 9-Day RSI is 7.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ceryvyn Therapeutics stock overvalued right now?
Ceryvyn Therapeutics (ASX:CYV) has a current 9-Day RSI of 7.34. The current 9-Day RSI is 7.34 and 85.2% below the Biotechnology industry median of 49.68. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Ceryvyn Therapeutics (ASX:CYV), the current 9-Day RSI is 7.34 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Opthea Ltd is engaged in researching and developing novel therapeutic products that target Vascular Endothelial Growth Factors (VEGF) C, D, and R3. The Group operates in one industry and two geographical areas, namely biotechnology and healthcare, with operations in Australia and the United States. The company focuses on developing biological therapeutics for eye diseases and is currently developing a novel biologic therapy, OPT-302, for the treatment of eye conditions. Its products are based on an intellectual property portfolio covering VEGF-C, VEGF-D, and VEGF Receptor-3 targets, aimed at treating diseases associated with blood and lymphatic vessel growth and vascular leakage.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CYV has been successfully added to your